Zhao Shihan, Liu Yuqi, Wang Han, Wang Jiayi, Zhang Jihong, Liu Yanbo, Ma Dongrui
School of Basic Medical College, Beihua University, Jilin, 132013, China.
The Pathology Department of Affiliated Hospital, Beihua University, Jilin, 132013, China.
Int Urol Nephrol. 2025 Apr 23. doi: 10.1007/s11255-025-04497-z.
Prostate cancer (PCa) is a leading cause of cancer-related morbidity and mortality in men worldwide. Despite advancements in diagnosis and treatment, challenges such as late-stage detection, therapeutic resistance, and the complexity of castration-resistant prostate cancer (CRPC) persist. Long non-coding RNAs (LncRNAs) play critical roles in PCa progression through epigenetic regulation, transcriptional and post-transcriptional modulation, and immune response regulation. This review highlights the molecular mechanisms by which LncRNAs influence PCa development, treatment resistance, and immune regulation, emphasizing their potential as biomarkers and therapeutic targets. We also discuss future research directions to advance precision medicine in PCa.
前列腺癌（PCa）是全球男性癌症相关发病和死亡的主要原因。尽管在诊断和治疗方面取得了进展，但诸如晚期检测、治疗耐药性以及去势抵抗性前列腺癌（CRPC）的复杂性等挑战依然存在。长链非编码RNA（LncRNAs）通过表观遗传调控、转录和转录后调节以及免疫反应调节在PCa进展中发挥关键作用。本综述重点介绍了LncRNAs影响PCa发展、治疗耐药性和免疫调节的分子机制，强调了它们作为生物标志物和治疗靶点的潜力。我们还讨论了推进PCa精准医学的未来研究方向。
